Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Schizophrenia, Disorganized AND Schizophrenia AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Schizophrenia, Disorganized AND Schizophrenia AND Placebo. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-024488-42 Sponsor Protocol Number: 2010-024488-42-PACS Start Date*: 2011-01-31
    Sponsor Name:Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Psychosisresearch
    Full Title: Pregabalin for anxiety comorbidity in patients with schizophrenia (PACS) - A Double-blinded Randomized Placebo Controlled Trial
    Medical condition: anxiety-comorbidity to schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10013387 Disorganized type schizophrenia LLT
    19.0 100000004873 10013386 Disorganised schizophrenia LLT
    19.0 100000004873 10007780 Catatonic schizophrenia LLT
    19.0 100000004873 10019364 Hebephrenic schizophrenia LLT
    19.0 100000004873 10033872 Paranoid schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000800-34 Sponsor Protocol Number: H8Y-MC-HBBI Start Date*: 2007-08-14
    Sponsor Name:Eli Lilly and Company Ltd.
    Full Title: A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia.
    Medical condition: Patients must have a diagnosis of Schizophrenia as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Disorganized, 295.10; Catatonic, 295.20; Paranoid, 295....
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039638 Schizophrenia, disorganised type PT
    9.1 10039637 Schizophrenia, catatonic type PT
    9.1 10039639 Schizophrenia, paranoid type PT
    9.1 10039640 Schizophrenia, residual type PT
    9.1 10052792 Schizophrenia, undifferentiated type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002682-40 Sponsor Protocol Number: 2005/150 Start Date*: 2006-08-07
    Sponsor Name:Aalborg Psychiatric Hospital, Research Unit
    Full Title: Augmenting clozapine with sertindole - A double-blinded randomized placebo study (SERCLOZ)
    Medical condition: Treatment resistant schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039638 Schizophrenia, disorganised type LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020370-42 Sponsor Protocol Number: NN25310 Start Date*: 2011-01-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020467-21 Sponsor Protocol Number: WN25309 Start Date*: 2010-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio en fase III multicéntrico aleatorizado, de 24 semanas, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes estables c...
    Medical condition: Tratamiento de los síntomas negativos en pacientes con esquizofrenia tratados con antipsicóticos Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001865-11 Sponsor Protocol Number: TV44749-CNS-30096 Start Date*: 2023-03-08
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Ola...
    Medical condition: Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucin...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006434-17 Sponsor Protocol Number: R092670PSY3007 Start Date*: 2007-05-03
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palm...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-020696-23 Sponsor Protocol Number: NN25307 Start Date*: 2011-03-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020616-11 Sponsor Protocol Number: WN25306 Start Date*: 2011-03-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020470-42 Sponsor Protocol Number: WN25308 Start Date*: 2011-01-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020718-26 Sponsor Protocol Number: WN25305 Start Date*: 2011-01-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004844-23 Sponsor Protocol Number: 20101299 Start Date*: 2012-06-12
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004845-42 Sponsor Protocol Number: 20110165 Start Date*: 2012-05-30
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002960-85 Sponsor Protocol Number: NN20372 Start Date*: 2008-03-18
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on select atypical antipsychotics with prominent negative or disorganized thought sy...
    Medical condition: Schizophrenia - This study will be conducted to investigate whether or not administration of RO4917838 along with their current antipsychotic regimen to stable patients can lead to further improvem...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001711-31 Sponsor Protocol Number: D1050238 Start Date*: 2012-02-29
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005271-14 Sponsor Protocol Number: D1050303 Start Date*: 2013-05-06
    Sponsor Name:Sunovion Pharmaceuticals Inc
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOW-DOSE LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENIA
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-020764-38 Sponsor Protocol Number: A8241012 Start Date*: 2010-12-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009134 Chronic schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000060-42 Sponsor Protocol Number: D1001066 Start Date*: 2017-03-15
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002048-29 Sponsor Protocol Number: RGH-MD-06 Start Date*: 2012-03-29
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-017852-28 Sponsor Protocol Number: H8Y-MC-HBBM(a) Start Date*: 2010-05-04
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:37:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA